Every Form 4 that Lyell Immunopharma, Inc. (LYEL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow LYEL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LYEL filings page.
Lyell Immunopharma, Inc. (LYEL) reported that Chief Medical Officer David Shook sold 500 shares of common stock on September 10, 2026 in an open-market transaction primarily to cover a tax withholding obligation from the settlement of vested restricted stock units. The shares were sold at a weighted average price of $12.70 per share, within a range of $12.32 to $12.70 per share. After this sale, Shook directly holds 20,423 shares of Lyell common stock, and no Rule 10b5-1 trading plan is reported for this transaction.
Lyell Immunopharma, Inc. (LYEL) reported that its Chief Medical Officer, Jarrad Mattieu Aguirre, received a stock option grant for 47,500 shares of common stock on September 10, 2026. The option has an exercise price of $12.20 per share and expires on September 9, 2036. According to the vesting terms, 12.5% of the option shares will vest on February 28, 2027, with the remainder vesting in equal monthly installments over the following 42 months, subject to continued service.
After this award, Aguirre holds 20,279 shares of common stock directly, which include 14,451 restricted stock units that vest quarterly over a thirty-month period following July 9, 2026, also conditioned on continued service. No Rule 10b5-1 trading plan is reported for these transactions.
Lyell Immunopharma, Inc. (LYEL) reported that its President and CEO, Lynn Seely, had an automatic sale of 9,589 shares of common stock on 2026-08-21 at $15.54 per share. The shares were sold to cover a tax withholding obligation from vested restricted stock units, leaving 63,899 shares held directly.
Lyell Immunopharma, Inc. (LYEL) reported that its Chief Operating Officer, Stephen J. Hill, had 989 shares of common stock automatically sold on 2026-08-21 at $15.54 per share. According to the disclosure, the sale was made to cover a tax withholding obligation arising from the settlement of vested restricted stock units, leaving 16,816 shares held directly.
Lyell Immunopharma, Inc. (LYEL) reported an insider transaction by Chief Scientific Officer Gary K. Lee. On 2026-08-21, 1,457 shares of common stock were sold at $15.54 per share. According to the disclosure, these shares were automatically sold to cover a tax withholding obligation from the settlement of vested restricted stock units, leaving 16,220 shares held directly after the transaction.
Lyell Immunopharma, Inc. officer Veronica Sanchez Bulis, VP and Corporate Controller, reported a sale of 621 shares of common stock on 2026-08-10 at a weighted average price of $14.34 per share, with sale prices ranging from $14.20 to $14.34. According to the disclosure, the shares were automatically sold to cover tax withholding obligations arising from the settlement of vested restricted stock units, rather than as a discretionary open-market sale. Following this transaction, Bulis directly holds 14,799 shares of Lyell Immunopharma common stock.
Lyell Immunopharma, Inc. Chief Scientific Officer Gary K. Lee reported an automatic sale of 131 shares of common stock on 2026-08-10 at a weighted average price of $14.34 per share. The shares were sold to satisfy a tax withholding obligation from the settlement of vested restricted stock units, leaving 17,677 shares held directly.
Lyell Immunopharma, Inc. executive Stephen J. Hill, Chief Operating Officer, reported an automatic sale of 89 shares of common stock on 2026-08-10. The shares were sold at a weighted average price of $14.34 per share, in a price range from $14.27 to $14.34 per share, to cover a tax withholding obligation arising from the settlement of vested restricted stock units. Following this transaction, Hill directly holds 17,805 shares of common stock.
Lyell Immunopharma, Inc. President and CEO Lynn Seely reported an automatic sale of 390 shares of common stock on 2026-08-10 to cover a tax withholding obligation from vested restricted stock units. The shares were sold at a weighted average price of $14.34 per share, within a range of $14.22–$14.34, leaving 73,488 shares held directly.
Innovative Cellular Therapeutics Holdings Ltd, a 10% owner of Lyell Immunopharma, Inc., transferred 44,000 shares of common stock to Wuxiong, Inc. as broker commission tied to a first Development Milestone under a license agreement. The transfer involved no cash consideration and is classified as an “other” disposition. After this transaction, the reporting holder beneficially owns 2,774,980 shares of Lyell common stock.
Innovative Cellular Therapeutics Holdings Ltd, a 10% owner of Lyell Immunopharma, transferred 38,500 shares of common stock on July 27, 2026 to LifeSci Advisors, LLC as broker commission related to the first Development Milestone payment under a November 6, 2025 license agreement. This non-cash disposition, reported under transaction code J, reduced its beneficial holdings to 2,818,980 shares of Lyell common stock.
Innovative Cellular Therapeutics Holdings Ltd, a ten percent owner of Lyell Immunopharma, Inc., reported a sale of 10 shares of common stock on July 17, 2026 at $13.70 per share. The filer indicated the trade was made under a Rule 10b5-1 trading plan. After this transaction, it directly beneficially owns 2,857,480 shares of Lyell common stock.
Innovative Cellular Therapeutics Holdings Ltd, a 10% owner of Lyell Immunopharma, Inc., reported a sale of 10 shares of Lyell common stock on 2026-07-16 at $13.73 per share. The trade was made pursuant to a Rule 10b5-1 trading plan, leaving the holder with 2,857,490 common shares afterward, down from 2,857,500 immediately before the sale.
Innovative Cellular Therapeutics Holdings Ltd, a major shareholder of Lyell Immunopharma, Inc., reported an internal share transfer classified as an "other" transaction. On June 29, it transferred 76,000 shares of Common Stock to Wuxiong, Inc. as broker commission related to an upfront payment under a prior license agreement, for no cash consideration.
Following this restructuring-type transfer, the reporting holder now beneficially owns 2,857,500 shares of Lyell common stock, down from 2,933,500 shares immediately before the transaction. The filing reflects a non-market, compensation-related movement of shares rather than an open-market purchase or sale.
Innovative Cellular Therapeutics Holdings Ltd, a 10% owner of Lyell Immunopharma, Inc., transferred 66,500 shares of common stock on June 15, 2026 to LifeSci Advisors, LLC as broker commission tied to an upfront payment under a license agreement. The transfer was made for no cash consideration and reported as an “other” transaction. Following this move, the reporting holder directly beneficially owns 2,933,500 shares of Lyell common stock.
Lyell Immunopharma, Inc. President and CEO Lynn Seely reported a small stock transaction related to taxes on equity compensation. On May 11, 2026, 388 shares of common stock were sold at a weighted average price of $18.91 per share to cover a tax withholding obligation from the settlement of vested restricted stock units. After this tax-related sale, Seely directly holds 73,878 shares of Lyell Immunopharma common stock, indicating that the transaction affects only a very small portion of her overall holdings and reflects a routine administrative disposition rather than a discretionary portfolio change.
Lyell Immunopharma, Inc. Chief Scientific Officer Gary K. Lee reported an automatic share sale tied to tax withholding. On May 11, 2026, 130 shares of common stock were sold at a weighted average price of $18.92 per share to cover tax obligations from the settlement of vested restricted stock units.
After this transaction, Lee directly held 17,808 shares of Lyell Immunopharma common stock. This total includes 1,000 shares acquired on May 18, 2026 under the company’s 2021 Employee Stock Purchase Plan, indicating that the filing reflects both routine compensation-related activity and associated tax withholding.
Lyell Immunopharma, Inc. Chief Operating Officer Stephen J. Hill reported an automatic sale of 89 shares of common stock on May 11, 2026 at a weighted average price of $18.92 per share. The shares were sold to cover tax withholding obligations from the settlement of vested restricted stock units. After this tax-related sale, Hill directly held 17,894 shares of Lyell Immunopharma common stock.
Lyell Immunopharma, Inc. VP and Corporate Controller Veronica Sanchez Bulis reported a small open-market sale of company common stock. She sold 217 shares on May 11, 2026, automatically to cover a tax withholding obligation from the settlement of vested restricted stock units.
The shares were sold at a weighted average price between $18.91 and $19.30 per share. After this tax-related sale, she directly owns 15,420 shares of Lyell Immunopharma common stock.
Lyell Immunopharma director William JL Rieflin received a new stock option grant for 9,250 shares of common stock. The option has an exercise price of $13.22 per share and expires on June 9, 2036.
According to the award terms, these option shares vest on the earlier of the next annual stockholder meeting following June 10, 2026 (or immediately before that meeting if his board service ends at that time) or the first anniversary of June 10, 2026, provided he continues serving through the vesting date. After this grant, his reported option holdings from this award total 9,250 shares.
Lyell Immunopharma director Sumant Ramachandra reported an equity award and updated holdings. He received an option grant covering 9,250 shares of common stock at an exercise price of $13.22 per share, expiring on June 9, 2036.
The option vests on the earlier of the next annual stockholder meeting following June 10, 2026 (or immediately before it if his board service ends at that meeting) or the first anniversary of that date, contingent on continuous service. In addition, 10,000 shares of common stock are held indirectly by the Sumant Ramachandra Rev Trust DTD 01/24/12, where he is grantor and trustee. All share amounts reflect a 1-for-20 reverse stock split effected on May 30, 2025.
Lyell Immunopharma director Elizabeth G. Nabel received a grant of stock options covering 9,250 shares of common stock. The options have an exercise price of $13.22 per share and were awarded as a compensation grant, not an open-market purchase or sale.
The options vest on the earlier of the next annual stockholder meeting following June 10, 2026 (or immediately before that date if her board service ends at that meeting), or the first anniversary of June 10, 2026, provided she continues serving as a director. The options expire on June 9, 2036, and following this grant she holds options to acquire 9,250 shares.
Lyell Immunopharma director Richard Klausner received a grant of 9,250 stock options for common stock, each with a $13.22 exercise price and expiring on June 9, 2036. This is a compensation-related award rather than an open-market purchase.
The options will vest on the earlier of the next annual stockholder meeting following June 10, 2026 (or immediately before it if he leaves the board at that meeting) or the first anniversary of that date, assuming continuous service. Following the reporting date, he held 148,391 common shares directly and 42,166 shares indirectly through family and Delaware trusts, with beneficial ownership of the Delaware trusts disclaimed except for any pecuniary interest. All share amounts reflect a 1-for-20 reverse stock split effective May 30, 2025.
Lyell Immunopharma director Cathy Friedman received a compensatory stock option grant for 9,250 shares of common stock. The option has an exercise price of $13.22 per share and expires on June 9, 2036. All share amounts reflect Lyell’s 1-for-20 reverse stock split effective May 30, 2025.
The option will vest on the earlier of the next annual stockholder meeting following June 10, 2026 (or immediately before that date if her board service ends at that meeting) or the first anniversary of June 10, 2026, subject to her continuous service. The filing also reports 5,000 shares held by The Duane Irrevocable Trust 2020 and 11,818 shares held by the Duane Family Trust, where Friedman is a trustee and disclaims beneficial ownership except to any pecuniary interest.
Lyell Immunopharma director Otis W. Brawley reported a new stock option grant. He received options to buy 9,250 shares of common stock at an exercise price of $13.22 per share, expiring on June 9, 2036.
The options vest on the earlier of the next annual stockholder meeting after June 10, 2026 or the first anniversary of that date, subject to his continued service as a director. Following the reported transactions, he holds 1,782 shares of common stock directly. All share amounts reflect a 1-for-20 reverse stock split effective May 30, 2025.
Lyell Immunopharma director Mark Bachleda received a grant of stock options for 9,250 shares of common stock. These options give him the right to buy 9,250 shares at an exercise price of $13.22 per share and expire on June 9, 2036.
The award is compensation-related and was not an open-market purchase. According to the vesting terms, all 9,250 option shares vest on the earlier of the next annual stockholder meeting after June 10, 2026, or the first anniversary of that date, provided he continues serving as a director through the vesting date.
Lyell Immunopharma Chief Medical Officer David Shook reported a small share sale primarily to cover taxes. On this Form 4, he sold 1,977 shares of common stock at $12.64 per share, with the shares automatically sold to satisfy tax withholding obligations from vested restricted stock units.
After this transaction, Shook directly owns 20,923 common shares, which includes 1,000 shares acquired on May 18, 2026 under Lyell’s 2021 Employee Stock Purchase Plan. The filing reflects a routine, tax-related disposition rather than a large discretionary sale.
Lyell Immunopharma reported that Chief Financial and Business Officer Smital Shah received a grant of options to buy 140,000 shares of common stock. The options have a $25.50 exercise price and expire on March 8, 2036. Twenty-five percent will vest on March 9, 2027, with the rest vesting in equal monthly installments over the following 36 months, contingent on continued service.
ARCH Venture funds increased their indirect stake in Lyell Immunopharma, Inc. by purchasing 488,090 shares of common stock in an open-market transaction on March 6, 2026, at $25.61 per share. The filing attributes ownership to ARCH Venture Fund IX-affiliated limited partnerships, with the general partner and managing directors disclaiming beneficial ownership beyond their pecuniary interests.
Lyell Immunopharma, Inc. reported an insider purchase by ARCH Venture Fund XIII, L.P. On March 6, 2026, ARCH Venture Fund XIII, L.P. made an open-market purchase of 488,090 shares of Lyell common stock at $25.61 per share, held indirectly through ARCH-related entities.
Following this transaction, ARCH Venture Fund XIII, L.P. held 1,426,528 Lyell shares. The filing also lists indirect holdings of 910,317 shares each for other ARCH-managed funds. General partners and investment committee members may be deemed beneficial owners but disclaim beneficial ownership except to the extent of any pecuniary interest.
Lyell Immunopharma’s President and CEO, Lynn Seely, reported an open‑market sale of company stock. On February 11, 2026, she sold 7,455 shares of common stock at a weighted average price of $23.39 per share. According to the filing, these shares were automatically sold to satisfy tax withholding obligations arising from the settlement of performance-based vested restricted stock units, rather than a discretionary sale of investment holdings. After this transaction, Seely directly beneficially owned 74,266 shares of Lyell Immunopharma common stock.
Lyell Immunopharma's Chief Operating Officer Stephen J. Hill reported an open-market sale of 1,236 shares of common stock on February 11, 2026. The shares were automatically sold to cover tax withholding obligations from the settlement of performance-based vested restricted stock units.
The sale was executed at a weighted average price of $23.39 per share, with individual trade prices ranging from $23.3939 to $24.7850 per share. Following this transaction, Hill directly beneficially owns 17,795 shares of Lyell Immunopharma common stock.
Lyell Immunopharma’s Chief Scientific Officer, Gary K. Lee, reported an open-market sale of 1,671 shares of common stock on February 11, 2026. The shares were automatically sold to cover tax withholding from performance-based vested restricted stock units.
The weighted average sale price was $23.39 per share, within a disclosed range of $23.3939 to $24.6305. After this tax-related sale, Lee directly beneficially owns 16,938 shares of Lyell Immunopharma common stock.
Lyell Immunopharma Chief Operating Officer Stephen J. Hill reported several equity transactions. He received 4,000 shares of common stock on February 9, 2026 from performance-based restricted stock units that vested after meeting certified performance criteria. On February 10, 2026 he was granted an option for 65,000 shares of common stock at an exercise price of $23.71 per share, with vesting beginning six months after February 9, 2026 and continuing monthly until fully vested, contingent on continued service. Also on February 10, he sold 109 shares at $23.12 per share to cover tax withholding from vested restricted stock units, leaving him with 19,031 common shares held directly.
Lyell Immunopharma’s Chief Scientific Officer Gary K. Lee reported several equity transactions. On February 9, 2026, he acquired 4,000 shares of common stock at $0 from performance-based restricted stock units, bringing his direct holdings to 18,756 shares.
On February 10, 2026, Lee was granted an option for 50,000 shares of common stock at an exercise price of $23.71, vesting over time through February 9, 2036. That same day, 147 shares were sold at $23.12 to cover tax withholding from vested restricted stock units, leaving him with 18,609 common shares held directly.
Lyell Immunopharma President and CEO Lynn Seely reported several equity compensation transactions. On February 9, 2026, Seely acquired 20,000 shares of common stock at $0, issued upon achievement of performance-based restricted stock unit criteria, bringing direct holdings to 82,159 shares.
On February 10, 2026, Seely sold 438 common shares at $23.12 per share, described as an automatic sale to cover tax withholding from vested restricted stock units, leaving 81,721 shares held directly. Also on February 10, Seely received a new option grant for 155,000 shares at an exercise price of $23.71 per share, vesting 12.5% six months after February 9, 2026 and then monthly in equal installments until fully vested, contingent on continued service.
Lyell Immunopharma General Counsel Mark A. Meltz received a grant of options to purchase 50,000 shares of common stock on February 10, 2026. The options have an exercise price of $23.71 per share and are held directly by him.
According to the vesting schedule, 12.5% of the shares subject to the option become vested and exercisable six months after February 9, 2026. The remaining shares vest in equal monthly installments of 1/48 of the total, so the option becomes fully vested over four years, contingent on his continued service.
Lyell Immunopharma VP, Corporate Controller Veronica Sanchez Bulis reported an equity grant and a small share sale. On February 10, 2026, she received 8,750 restricted stock units under Lyell’s 2021 Equity Incentive Plan at $0 per share equivalent, increasing her holdings to 15,891 common shares.
The RSUs vest over time: 12.5% on August 9, 2026, then 1/16 of the total vests quarterly, as long as she continues providing service. The filing also shows an open-market sale of 254 common shares at $23.12 per share, executed automatically to cover tax withholding from vested RSUs, leaving her with 15,637 directly owned shares.
Lyell Immunopharma Chief Medical Officer David Shook received a grant of stock options. On February 10, 2026, he was awarded an option to buy 50,000 shares of Lyell Immunopharma common stock at an exercise price of $23.71 per share.
The option vests over time: 12.5% of the shares become exercisable six months after February 9, 2026, and the remaining shares vest in equal monthly installments until fully vested, as long as he continues providing service. Following this grant, he also directly held 21,900 shares of common stock.
Lyell Immunopharma VP Veronica Sanchez Bulis reported two sales of company stock. On 12/24/2025 she sold 1,136 shares of common stock at a weighted average price of $38.67 per share, in a series of trades where individual prices ranged from $38.6643 to $38.6751 per share. On 12/30/2025 she sold an additional 936 shares at $32.32 per share. After these transactions, she held 7,141 shares of Lyell Immunopharma common stock directly.
Lyell Immunopharma (LYEL) reported an insider transaction by its President and CEO, who is also a Director. On 11/10/2025, the insider sold 412 shares of common stock at $16.11 per share. The filing states these shares were automatically sold to cover tax withholding from the settlement of vested restricted stock units. Following the transaction, the insider beneficially owns 67,159 shares, held directly.
Lyell Immunopharma (LYEL) reported an insider transaction by its VP, Corporate Controller. On 11/10/2025, the officer sold 239 shares of common stock at a weighted average price of $16.10.
The filing states the shares were automatically sold to cover tax withholding from the settlement of vested RSUs. Following the transaction, the officer beneficially owns 9,213 shares, held directly.
Lyell Immunopharma (LYEL) reported an insider transaction by its Chief Operating Officer on a Form 4. The filing shows an automatic sale of 95 shares of common stock at $16.12 on 11/10/2025 to satisfy tax withholding from the settlement of vested restricted stock units.
Following this tax-related sale, the reporting person directly holds 15,750 shares of Lyell common stock.
Lyell Immunopharma (LYEL) reported insider activity by its Chief Operating Officer via Form 4. On 10/27/2025, the officer received an option to buy 75,000 shares of common stock at an exercise price of $17.23. The award vests with 12.5% of the option shares on April 27, 2026, and the remainder in equal monthly installments over the following 42 months, subject to continued service. Following the reported transactions, the officer beneficially owned 15,845 shares of common stock, held directly.
Lyell Immunopharma (LYEL) reported an insider equity award. The company’s Chief Scientific Officer filed a Form 4 showing an option grant for 68,000 shares with an exercise price of $17.23 on 10/27/2025. These options expire on 10/26/2035.
Vesting is staged: 12.5% vests on 4/27/2026, with the remainder vesting in equal monthly installments over the following 42 months, contingent on continued service. Following the reported transactions, the insider reported 15,504 shares of common stock beneficially owned, held directly.
Lyell Immunopharma (LYEL) reported an insider equity award. The reporting person, who serves as President, CEO and Director, acquired 175,000 stock options on 10/27/2025 at an exercise price of $17.23, expiring on 10/26/2035.
Vesting is scheduled with 12.5% on April 27, 2026, and the remainder in equal monthly installments over the following 42 months, subject to continued service. Following the reported transactions, the insider beneficially owns 67,571 shares of common stock.